【Nucleai完成1400万美元B+轮融资，引领AI空间生物标志物分析新纪元】
AI驱动的空间生物标志物分析初创公司Nucleai近日宣布，成功完成了1400万美元的B+轮融资，本次投资由知名投资机构M Ventures领投。参与跟投的包括现有投资者Section 32、Sanofi Ventures、Debiopharm、复星锐正资本、Vertex Ventures Israel以及Grove Ventures等，显示出业界对Nucleai技术前景的广泛认可。
Nucleai致力于利用人工智能和机器学习技术，革新病理图像和空间数据的分析方式，特别是在细胞和组织层面的深度解析。通过其创新平台，公司能够预测疾病治疗效果，为精准医疗提供强有力的支持。这一技术的应用有望极大地推动生物医学研究和临床实践的进步。
本次融资的成功，不仅为Nucleai的进一步研发和市场拓展提供了资金保障，也标志着公司在AI驱动的生物医学分析领域取得了新的里程碑。Nucleai表示，将利用这笔资金加速产品研发，扩大团队规模，并加强与全球合作伙伴的深度合作，以期在不久的将来为医疗行业带来革命性的变革。
据消息来源CTech透露，Nucleai的解决方案已经在业界引起了广泛关注，其独特的技术优势和潜在的临床应用价值，使得该公司在生物科技与人工智能的交叉领域中脱颖而出。随着新一轮资金的注入，Nucleai正蓄势待发，准备在这一前沿领域开启新的篇章。
英语如下：
**News Title:** “Nucleai, an AI Biomarker Analysis Company, Secures $14M in B+ Funding, Pioneering a New Era in Pathological Image Analysis”
**Keywords:** AI bioanalysis, Nucleai funding, pathology image recognition
**News Content:**
**Nucleai Completes $14M B+ Funding Round, Paving the Way for a New Era in AI-Powered Spatial Biomarker Analysis**
AI-driven spatial biomarker analysis startup Nucleai recently announced that it has successfully closed a $14 million B+ funding round, led by prominent investor M Ventures. Participating in the round were existing backers Section 32, Sanofi Ventures, Debiopharm, Fosun RZ Capital, Vertex Ventures Israel, and Grove Ventures, demonstrating a broad industry endorsement of Nucleai’s technological prospects.
Nucleai is dedicated to revolutionizing the analysis of病理图像 and spatial data using artificial intelligence and machine learning techniques, particularly in the deep profiling of cells and tissues. Through its innovative platform, the company can predict disease treatment outcomes, thereby significantly contributing to precision medicine. This technology has the potential to make a substantial impact on advancements in biomedical research and clinical practice.
The successful funding not only ensures financial support for Nucleai’s continued R&D and market expansion but also signifies a new milestone in the company’s AI-driven biomedical analytics journey. Nucleai plans to utilize the funds to accelerate product development, expand its team, and deepen collaborations with global partners, aiming to bring about a transformative change in the healthcare industry in the near future.
According to sources at CTech, Nucleai’s solutions have already garnered significant industry attention. The company’s unique technological advantages and potential clinical application value have set it apart in the intersection of biotechnology and artificial intelligence. With this new influx of capital, Nucleai is poised to embark on a new chapter in this cutting-edge field.
【来源】https://www.calcalistech.com/ctechnews/article/r11brac1a
Views: 1